Project 1: WWOX Restoration via Targeted Delivery
Concept: Restore the tumor-suppressing function of the WWOX protein in pancreatic cancer cells.
Technology: Utilize viral vectors and proprietary biodegradable nanoparticles to deliver WWOX mRNA specifically to pancreatic cancer cells.
Stage: Preclinical.
Next Steps:
Optimize mRNA delivery and expression.
Evaluate efficacy in in vivo models.
Explore combination therapy with small molecule inhibitors identified through organoid screening.
Estimated Timeline to Clinical Trial: 2-3 years
Project 2: TP53 Gene Correction via CRISPR/Cas9
Concept: Correct mutations or insert functional copies of the TP53 tumor suppressor gene in pancreatic cancer cells.
Technology: Employ CRISPR/Cas9 gene editing to restore TP53 function.
Stage: Preclinical.
Next Steps:
Design and validate guide RNAs for precise targeting of TP53 mutations.
Optimize gene editing efficiency and minimize off-target effects.
Evaluate efficacy in in vitro and in vivo models.
Estimated Timeline to Clinical Trial: 3-4 years
Project 3: KRAS and EGFR Disruption via CRISPR/Cas9
Concept: Disrupt the function of the KRAS and EGFR oncogenes in pancreatic cancer cells.
Technology: Utilize CRISPR/Cas9 gene editing to knock out KRAS and EGFR
Stage: Discovery.
Next Steps:
Conduct comprehensive genomic analysis to identify specific KRAS and EGFR mutations in pancreatic cancer.
Design and validate guide RNAs for precise targeting of KRAS and EGFR.
Develop and validate in vitro and in vivo models.
Estimated Timeline to Clinical Trial: 4-5 years